©2022 Stanford Medicine
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Not Recruiting
Trial ID: NCT02429804
Purpose
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/
fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging
(MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating
patients with prostate cancer that has not responded to hormone therapy and has spread to
other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors
accurately measure how well patients respond to treatment with radium Ra 223 dichloride.
Official Title
Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Provides written informed consent
- Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223
dichloride)
- Able to remain still for duration of the imaging procedure (about one hour)
Exclusion Criteria:
- Metallic implants
Intervention(s):
procedure: Contrast-enhanced Magnetic Resonance Imaging
procedure: Magnetic Resonance Imaging
procedure: Positron Emission Tomography
drug: Fludeoxyglucose F-18
drug: Fluorine F 18 Sodium Fluoride
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Omar Rutledge
650-721-4089